Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells by unknown
ARTICLE
Nutrient-dependent secretion of glucose-dependent
insulinotropic polypeptide from primary murine K cells
H. E. Parker & A. M. Habib & G. J. Rogers &
F. M. Gribble & F. Reimann
Received: 29 August 2008 /Accepted: 16 October 2008 / Published online: 11 December 2008
# The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Glucose-dependent insulinotropic poly-
peptide (GIP) is an incretin hormone with anti-apoptotic
effects on the pancreatic beta cell. The aim of this study
was to generate transgenic mice with fluorescently labelled
GIP-secreting K cells and to use these to investigate
pathways by which K cells detect nutrients.
Methods Transgenic mice were generated in which the GIP
promoter drives the expression of the yellow fluorescent pro-
tein Venus. Fluorescent cells were purified by flow cytometry
and analysed by quantitative RT-PCR. GIP secretion was
assayed in primary cultures of small intestine.
Results Expression of Venus in transgenic mice was restricted
to K cells, as assessed by immunofluorescence and measure-
ments of theGip mRNA and GIP protein contents of purified
cells. K cells expressed high levels of mRNA for Kir6.2
(also known as Kcnj11), Sur1 (also known as Abcc8), Sglt1
(also known as Slc5a1), and of the G-protein-coupled lipid
receptors Gpr40 (also known as Ffar1), Gpr119 and Gpr120.
In primary cultures, GIP release was stimulated by glucose,
glutamine and linoleic acid, and potentiated by forskolin
plus 3-isobutyl-1-methylxanthine (IBMX), but was unaffect-
ed by the artificial sweetener sucralose. Secretion was half-
maximal at 0.6 mmol/l glucose and partially mimicked by
α-methylglucopyranoside, suggesting the involvement of
SGLT1. Tolbutamide triggered secretion under basal conditions,
whereas diazoxide suppressed responses in forskolin/IBMX.
Conclusions/interpretation These transgenic mice and
primary culture techniques provide novel opportunities to
interrogate the mechanisms of GIP secretion. Glucose-
triggered GIP secretion was SGLT1-dependent and modu-
lated by KATP channel activity but not determined by sweet
taste receptors. Synergistic stimulation by elevated cAMP
and glucose suggests that targeting appropriate G-protein-
coupled receptors may provide opportunities to modulate
GIP release in vivo.
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Abbreviations
αMG α-methyl glucopyranoside




GLP-1 glucagon-like peptide 1
GPR40, 119, 120 G-protein-coupled receptor 40,
119, 120
IBMX 3-isobutyl-1-methylxanthine
KATP ATP-sensitive potassium channel
OEA oleoylethanolamide
PMA phorbol 12-myristate 13-acetate
SGLT1 sodium-dependent glucose
transporter 1
Glucose-dependent insulinotropic polypeptide (GIP) is an
intestinal hormone that promotes insulin release and
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coordinates the fate of dietary fat. Together with glucagon-
like peptide 1 (GLP-1), it is responsible for around 50% of
the normal release of insulin following glucose ingestion, a
phenomenon termed the incretin effect [1, 2]. In addition,
GIP has been reported to stimulate fat deposition directly in
adipocytes and has been postulated to link overnutrition to
obesity [3–5].
Whilst the GLP-1 axis has proved a fruitful target for
new glucose-lowering drugs, with both GLP-1 mimetics
and inhibitors of GLP-1 degradation available for the
treatment of type 2 diabetes [6], it is currently uncertain
whether GIP receptor agonists will prove to be similarly
beneficial, as pharmacological doses of GLP-1, but not GIP,
have been shown to increase insulin release in this patient
group [7]. The difference may be due, in part, to receptor
desensitisation, which is rapid for GIP receptors and
enhanced by hyperglycaemia [8]. Nevertheless, GIP, like
GLP-1, has beneficial proliferative and anti-apoptotic
effects on pancreatic islet cells [9], and dipeptidyl peptidase
IV-resistant GIP analogues have been shown to improve
glucose homeostasis in normal, obese and diabetic rodents
[10, 11].
By contrast, there is increasing evidence that GIP plays a
role in fat metabolism and that inhibiting the GIP axis may
be of therapeutic value in obesity [12]. Thus, GIP-receptor
knockout mice, whilst mildly glucose-intolerant [13], were
protected against obesity in high-fat-fed and ob/ob models
[14], and chronic interruption of GIP signalling by GIP
receptor antagonists or K cell ablation was shown to have
beneficial effects on weight gain, insulin sensitivity and
glucose tolerance in various rodent models of obesity [15–
17]. As antagonising GIP results in an acute reduction in
glucose-triggered insulin secretion, as expected [18, 19], it
is currently unclear whether its longer-term beneficial
effects are due to the reduced circulating insulin levels or
to the loss of extrapancreatic actions of GIP [20].
GIP secretion is triggered by the ingestion of carbohy-
drate or fat, elevated levels being detectable in the plasma
within 10–20min [21, 22]. As the GIP-containing K cells
are located in the duodenal and jejunal epithelia and have
apical surfaces opening into the gut lumen [23, 24], they are
believed to sense luminal nutrients directly. Studies on
isolated perfused rodent intestine have suggested that
carbohydrate detection by K cells involves the sodium-
dependent sugar uptake pathway, as the potency of different
monosaccharides to trigger GIP release was found to match
the properties of the intestinal Na+-coupled glucose trans-
porters (e.g. sodium-dependent glucose transporter 1,
SGLT1) [25, 26]. The finding that the SGLT inhibitor
phloridzin impaired glucose-stimulated GIP secretion in
rodent intestine [25] supported this view and further
indicated that the mere presence of sugars in the gut lumen
is not sufficient to trigger GIP secretion [27].
At the cellular and molecular levels very little is known
about how K cells respond to glucose and other stimuli,
largely because there is a lack of validated cell models for
studying GIP release in vitro. GIP-releasing cell lines have
been developed by subcloning STC-1 cells, but the STC-1
cell line was developed originally as a model of secretin
secretion and also produces a wide range of other enter-
oendocrine peptides, including GLP-1 and cholecystokinin
[28]. Although potentially useful for the identification of
pathways in enteroendocrine cells in general, it is less clear
whether results from STC-1 cells accurately mirror the
behaviour of native K cells. Nevertheless, as identifying
and culturing primary K cells has been fraught with dif-
ficulties, the use of such cell lines has so far provided the
only reproducible method to study GIP secretion in vitro.
Although K cells are traditionally considered to be a
distinct subset of enteroendocrine cells, there are reports in
the literature of a subpopulation of K cells which stain for
GLP-1 as well as GIP [29]. It is therefore perhaps not too
surprising that the monosaccharide sensitivity of GIP
secretion found in perfused intestinal preparations is similar
to that reported for GLP-1 secretion, suggesting that similar
mechanisms might underlie the glucose-dependent release
of these two hormones. We previously reported that sugar-
triggered GLP-1 secretion in the cell line GLUTag is
determined by the activity of SGLTs, which can excite cells
as a result of the coupled uptake of one or two Na+ ions for
each molecule of glucose transported [30]. This generates a
small inward current that is sufficient to depolarise the
cells, triggering the firing of action potentials and Ca2+
entry through L-type voltage-gated Ca2+ channels. In addi-
tion, GLUTag cells express functional ATP-sensitive K+
(KATP) channels, the closure of which by glucose metabo-
lism or sulfonylureas contributes to enhanced cell excit-
ability and GLP-1 secretion [31]. By contrast, studies of
GIP secretion using an STC-1 subclone (GIP/ins) suggested
that nutrient sensing arises from the metabolic inhibition of
AMP-dependent kinase-related kinases [32], and that native
K cells do not express KATP channels [33]. It has also been
proposed recently that glucose sensing by K and L cells
may involve sweet taste receptor pathways, and that these
enteroendocrine cells thereby resemble sweet-responsive
lingual chemosensory cells [34, 35].
To enable the identification and characterisation of pri-
mary GIP-secreting K cells, we generated transgenic mice
expressing a yellow fluorescent protein (Venus) under the
control of the GIP promoter (GIP-Venus mice). Fluorescent
intestinal cells from these mice, purified by flow cytometry,
were used to identify the glucose-sensing machinery
expressed in native K cells by quantitative RT-PCR and to
evaluate the expression of certain lipid-sensitive G-protein-
coupled receptors that have been postulated to play a role in
fat detection by enteroendocrine cells. We also established
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primary cultures of adult mouse small intestine and used this
model to investigate the functional properties of primary
cultured K cells.
Methods
Generation of transgenic mice Bacterial artificial chromo-
some (BAC) constructs containing the sequence of Venus
driven by the rat GIP promoter were made by the RedEt
technique [36] (see Electronic supplementary material
[ESM]). Mice were bred in-house and animal procedures
were approved by the local ethics committee and con-
formed to UK Home Office regulations.
Intestinal epithelial cell isolation for flow cytometry Venus-
expressing transgenic mice aged 2–6 months were killed by
cervical dislocation and the gut was collected into ice-cold
Leibovitz-15 (L-15) medium (PAA Laboratories, Yeovil,
UK). The upper small intestine (incorporating 10–15 cm of
gut, immediately distal to the pylorus), was opened, rinsed
in L-15 and chopped into 1–2 mm pieces. Tissue was
digested twice for 30 min with 1 mg/ml collagenase-XI in
calcium-free Hanks’ balanced salt solution at 37°C. Cell
suspensions were filtered through 70 μm nylon strainers
(BD Biosciences, Bedford, MA, USA) and centrifuged at
300 g for 5 min, and pellets were resuspended in L-15
supplemented with 10% (vol./vol.) fetal bovine serum
(FBS).
Flow cytometry A Cytomation MoFlo cell sorter (488 nm
excitation; Beckman Coulter, High Wycombe, UK) was
used to separate populations of >95% pure Venus-positive
or -negative cells. Settings were as follows: 90 μm nozzle,
38–40 psi, 58–60 kHz, plates charged at 3,200 V. Single
cells were selected by their side and forward scatter and
pulse width. Venus-positive cells were selected by their
fluorescence at 530 and 580 nm, and Venus-negative cells
by a gate that excluded Venus fluorescence. Cells were
sorted into RNAlater (Ambion, Austin, TX, USA) or lysis
buffer for protein extraction (see below).
RNA extraction and quantitative RT-PCR Total RNA from
FACS-sorted cells was isolated using a microscale RNA
isolation kit (Ambion) according to the manufacturer’s
instructions. RNA was reverse-transcribed according to
standard protocols. Quantitative RT-PCR was performed with
a 7900 HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA, USA). The PCR reaction mix consisted of
first-strand cDNA template, primer pairs (see ESM Table 2),
6-carboxyfluorescein/quencher probes (Bioresearch Technol-
ogies, Novato, CA, USA and Applied Biosystems) and PCR
Master Mix (Applied Biosystems). Expression was com-
pared with that of β-actin (Actb) measured on the same
sample in parallel, giving a CT difference (ΔCT) for β-actin
minus the test gene. Reactions in which the test gene was
undetectable were assigned a CT value of 40, and where
mRNA was detectable in fewer than two samples, this is
marked in Table 1.
Immunohistochemistry Freshly isolated mouse duodenum/
jejunum was fixed in 4% (wt/vol.) para-formaldehyde for
48 h, cryoprotected in 20% (wt/vol.) sucrose for 48 h and
embedded in OCT (optimum cutting temperature com-
pound) prior to sectioning. Duodenal/jejunal sections
(7 μm) were first permeabilised with 0.1% (vol./vol.) Triton
X-100, blocked with 10% (vol./vol.) goat serum in PBS, and
incubated with a GIP antibody (1:250; Millipore, Billerica,
MA, USA) overnight at 4°C. For SGLT1 staining of tissue
sections, an antigen retrieval step was required. Briefly,
sections were heated at 125°C for 3 min in trisodium citrate
buffer (10 mmol/l, pH6), allowed to cool, rinsed with PBS
and blocked as described above. Subsequently, sections
were incubated with an SGLT1 antibody (1:100) [37] for 3 h
at room temperature. Because of the loss of Venus fluores-
cence as a consequence of antigen retrieval, a fluorescein
isothiocyanate-conjugated GFP antibody (1:100; Abcam,
Cambridge, UK) was also added for 3 h to label the K cells.
Table 1 Gene expression in Kpos and Kneg cells measured by
quantitative RT-PCR
Gene Kpos cells Kneg cells p value (Kpos vs Kneg)
Gip +8.0±0.6 −4.0±1.0 0.00013
Gcg −4.4±0.6 −7.5±1.2 0.022
Pyy +0.1±1.0 −9.5±1.2 0.00055
Kir6.2 −1.5±0.4 −9.1±1.8 0.0054
Sur1 −0.1±0.1 −9.0±0.7 0.00023
Gck −3.2±0.3 −11.9±1.7 0.0074
Sglt1 −1.2±0.3 −1.4±0.3 0.75
Glut1 −6.8±0.9 −7.1±0.2 0.78
Glut2 −5.6±0.2 −3.7±0.3 0.0080
Glut3 −12.9±0.4 (<) −11.5±0.9 –
Glut5 −2.9±0.2 −4.0±0.2 0.026
Tas1R1 −11.0±1.5 −15.3±1.3 0.10
Tas1R2 −13.3±0.3 (<) −14.0±0.6 (<) –
Tas1R3 −8.2±1.9 −9.6±0.5 0.52
Gnat3 −15.9±1.0 (<) −15.7±1.3 (<) –
Gpr40 −1.7±0.3 −8.3±1.3 0.0071
Gpr120 −3.2±0.5 −9.5±0.7 0.0020
Gpr119 −4.7±0.8 −13.1±1.1 0.00086
Data are CT differences (ΔCT), i.e. the CT for β-actin minus the CT
for the gene of interest measured in parallel in the same sample
(±SEM)
CTs were allocated a value of 40 if the gene was not detected
(<) marks data where fewer than two samples gave a detectable
reading for the test gene, indicating that the expression level was less
than the value indicated
Significance was compared by Student’s t test
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Bound SGLT1 and GIP antibodies were detected using an
Alexa 633-conjugated secondary antibody (1:500; Invitro-
gen, Paisley, UK). Tissue samples stained with the secondary
antibody alone served as a control. All presented images were
captured using a Zeiss LSM 510 Meta confocal microscope
(Carl Zeiss, Welwyn Garden City, UK) with a 63×/NA 1.4
objective, at a resolution of 1,024 × 1,024 pixels and an
optical slice thickness of 1.5 μm.
Primary crypt culture Intestinal tissue from the top half of
the small intestine, collected as above, was digested with
0.4 mg/ml collagenase XI. Digested tissue was centrifuged
at 300 g and resuspended in Dulbecco’s modified Eagle
medium (25 mmol/l glucose) supplemented with 10%
(vol./vol.) FBS, 2 mmol/l L-glutamine, penicillin and
streptomycin. This tissue suspension was plated on Matrigel
(BD Biosciences, Bedford, MA, USA) -coated 24-well plates
and incubated at 37°C under 5% CO2.
GIP secretion Secretion studies were performed 24–36 h
after plating, using primary cultures of small intestine tissue
from either GIP-Venus or control mice. As preliminary
experiments showed that expression of the fluorescent
transgene in K cells did not affect GIP secretion in vitro,
transgenic and control mice were thereafter used inter-
changeably. Cultures were washed thoroughly and incubat-
ed in the presence or absence of test reagents in bath
solution (see below) containing 0.1% (wt/vol.) fatty acid-
free BSA for 2–4 h at 37°C. The medium was collected and
centrifuged to remove any contaminating cells. The plated
cells were then treated with lysis buffer containing: 50 mmol/l
Tris–HCl, 150 mmol/l NaCl, 1% (vol./vol.) Igepal-CA 630,
0.5% (wt/vol.) deoxycholic acid and one tablet of com-
plete EDTA-free protease inhibitor cocktail (Roche, Basel,
Switzerland). Plates were freeze–thawed and mechanically
disrupted to extract intracellular GIP. GIP was assayed in
the supernatant fraction and cell extracts using an enzyme-
linked immunosorbent assay (GIP Total ELISAKit; Millipore).
GIP secretion in each well was expressed as a fraction of the
total GIP measured in that well, and was normalised, as
indicated, to the basal secretion measured in parallel on the
same day.
Solutions The standard bath solution contained (mmol/l):
4.5 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2,
1.2 MgCl2 and 10 HEPES (pH7.4, NaOH). Oleoylethano-
lamide (OEA), forskolin (fsk) and IBMX were prepared as
1,000× stock solutions in DMSO, phloridzin as a 1,000×
stock in ethanol, tolbutamide as a 100 mmol/l stock solution
in NaOH, and diazoxide as a 68 mmol/l stock solution in
NaOH. Other agents were dissolved directly in bath
solution. All chemicals were supplied by Sigma Aldrich
(Poole, UK) unless otherwise stated.
Data analysis For expression data, mean, standard error
and significance calculations were performed on the raw
ΔCT data. Statistical comparisons were performed by
Student’s two- or one-sample t test or regression analysis,
as indicated, with a threshold for significance of p = 0.05.
Results
Generation and characterisation of transgenic mice Trans-
genic mice were created using a construct based on a BAC
containing ~200 kb around the rat Gip locus, in which the
Gip coding sequence was replaced by that of Venus
(Fig. 1a). We generated two founder strains that faithfully
transmitted the transgene to their offspring, each containing
a single copy number, as assessed by quantitative PCR. The
GIP-Venus mice had yellow fluorescent cells in their gut
epithelium, readily visible in living tissue specimens by
epifluorescence microscopy. The highest density of fluores-
cent cells occurred in the duodenum and jejunum, consistent
with the previously reported localisation of K cells [38].
Immunofluorescence staining with a GIP antibody con-
firmed that expression of the transgene was K cell-specific
(Fig. 1b), and as no difference was observed between the
two strains they were used interchangeably for the
remainder of the study.
By flow cytometry, we collected populations of up to
20,000 Venus-positive K cells (Kpos) at a purity of ~95%, as
assessed by direct epifluorescence microscopy (Fig. 2a–e),
as well as control (Venus-negative) cells (Kneg). Kpos cells
contained 4000-fold more Gip message and 2,000-fold more
GIP protein than Kneg cells, confirming that the fluorescent
marker was correctly targeted to the K cell population
Fig. 1 Generation of transgenic mice and confirmation of cell-
specific Venus expression. a The BAC construct for making
transgenic mice was made by cloning Venus into the coding region
of Gip (for further details see ESM). b Colocalisation of direct Venus
fluorescence (green) with GIP immunofluorescence (red) in the small
intestine. Scale bar, 20 μm
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(Fig. 2f, g; Table 1). Levels of Gip mRNA and GIP protein
were eightfold and sixfold higher, respectively, in Kpos cells
than in fluorescently tagged GLP-1-producing L cells from
the small intestine [39].
Kpos cells expressed ninefold higher levels of progluca-
gon (GCG) and 780-fold higher levels of mRNA for peptide
YY (Pyy) than Kneg cells (Fig. 2h, i). By comparison, how-
ever, small intestinal L cells had 90-fold more Gcg mRNA
(p = 0.0007) and >60-fold more GLP-1 protein than Kpos
cells, but similar levels of Pyy mRNA (data not shown).
Expression of glucose-sensing machinery To identify the
glucose-sensing machinery expressed in K cells, we compared
the expression in Kpos and Kneg cells of a range of candidate
glucose-sensing components, including KATP channel sub-
units (Kir6.2 [also known as Kcnj11], Sur1 [also known as
Fig. 3 Expression of candidate glucose-sensing machinery in K cells.
a–f Histograms showing relative gene expression of KATP channel
subunits (Kir6.2, Sur1), Gck, Sglt1, Glut2 and Glut5 in Kpos (black
columns) and Kneg cells (white columns) from the upper small
intestine. Expression was analysed by quantitative RT-PCR and
compared with that of β-actin in the same sample. Each column
represents three to six samples from separate mice. Data are presented
as geometric mean, and the error bars were calculated from the log
(base 2) data. Significance comparisons between Kpos and Kneg cells
were calculated by Student’s t test; *p<0.05, **p<0.01, ***p<0.001.
g Immunostaining for Venus (green) and SGLT1 (red) in the
duodenum/jejunum, showing the apical localisation of SGLT1 on the
villus. Because of the thickness of the optical slice (1.5 μm), only
the apical tip of the K cell can be clearly seen. Scale bar, 20 μm
Fig. 2 Collection and analysis of Venus-positive and control cells
from the intestine. Single-cell enzymatic digest of the upper small
intestine from a GIP-Venus mouse, before (a, b) and after (c, d) FACS
sorting. Differential interference contrast (DIC) images are shown
(a, c), with the corresponding fluorescence at 488 nm excitation (b, d).
After FACS sorting, >95% of the collected cells were Venus-positive.
Scale bar, 30 μm. e K cells were collected from the upper small
intestine by FACS sorting, using gates on pulse width and side and
forward scatter to select single cells, and on yellow (580 nm) and
green (530 nm) fluorescence to select either Venus-positive (R1) or
Venus-negative cells. The excitation wavelength was 488 nm.
f Histogram showing GIP protein content in unsorted, Kpos and Lpos
cells from the upper small intestine. GIP content was analysed after cell
extraction by ELISA. Lpos cells were FACS-sorted in a similar way to
Kpos cells, using a transgenic mouse expressing Venus under the
control of the proglucagon promoter [39]. Each bar represents three or
four samples from different mice. **p<0.01, ***p<0.001 (Student’s
t test) g, h, i Histograms showing relative gene expression of Gip, Gcg
and Pyy in Kpos (black columns) and Kneg cells (white columns) from
the upper small intestine. Expression was analysed by quantitative RT-
PCR and compared with that of β-actin in the same sample. Three to
six samples from separate mice were analysed for each bar. Data are
presented as geometric mean, and the error bar was calculated from the
log(base 2) data. Significance differences between Kpos and Kneg cells
were found using Student’s t test; *p<0.05, ***p<0.001
Diabetologia (2009) 52:289–298 293
Abcc8]), glucokinase (Gck) and Sglt1 (also known as Slc5a1),
facilitative glucose transporters (Glut1, -2, -3 and -5 [also
known as Slc2a1, -2, -3 and -5]), taste receptor subunits
(Tas1r1, -2 and -3) and α-gustducin (Gnat3). Gene expres-
sion levels of Kir6.2, Sur1 and Gck were higher in Kpos than
Kneg cells by 190-fold, 470-fold and 420-fold, respectively
(Fig. 3a and Table 1). In comparison with expression levels
measured in pancreatic beta cells (F. Gribble, unpublished
data), Kpos cells had similar levels of Kir6.2 and Gck
expression and only twofold lower expression of Sur1. Both
Kpos and Kneg cells exhibited high expression of Sglt1, and
the protein was localised to the apical surface by immuno-
fluorescence staining (Fig. 3b) Expression of facilitative
glucose transporters in Kpos cells was detected in the relative
orderGlut5>Glut2>Glut1>Glut3, and whereas Glut1, -3 and -5
were expressed at similar levels in Kpos compared with Kneg
cells, Glut2 expression was fourfold lower in the Kpos than
Kneg cells (p = 0.008). Of the sweet taste receptor subunits
(made up of Tas1r2 and Tas1r3), Tas1r3 expression was
detectable at similar levels in both Kpos and Kneg cells
(Table 1), but Tas1r2 and Gnat3 expression levels were
below the detection limit in Kpos cells.
Nutrient-stimulated GIP secretion in vitro We next inves-
tigated the nutrient sensitivity of GIP secretion in vitro,
Fig. 4 Glucose-dependent GIP secretion from primary intestinal
cultures. a Mixed intestinal cultures from the upper small intestine
were incubated for 2–4 h in bath solution containing additions as
indicated: control (Con), glucose (0.1, 1 or 10 mmol/l), glutamine
(Gln, 10 mmol/l), fructose (Fruct, 10 mmol/l), tolbutamide (Tolb,
500 μmol/l) or αMG (10 mmol/l). Number of wells: glucose 0.1, 1,
10 mmol/l, 11, 13, 27, respectively; Gln, 12; Fruct, 9; Tolb, 19; αMG,
12. GIP was measured in the supernatant fraction and cell extracts,
and is expressed relative to basal secretion measured in parallel on the
same day (indicated by dashed line). Error bars represent 1 SE and
significance is shown relative to baseline, analysed by single-factor
t test; *p<0.05, **p<0.01. b Responsiveness of GIP secretion to a
higher concentration of glucose (100 mmol/l) compared with
sucralose (1 mmol/l), PMA (1 μmol/l) or fsk/IBMX (10 μmol/l of
each). Number of wells: glucose, 13; sucralose, 5; PMA, 3; fsk/IBMX,
53. Experiments were carried out as in a. Error bars represent 1 SE,
and significance is shown relative to baseline (shown by the dashed
line) using a single-factor t test; **p<0.01, ***p<0.001
Fig. 5 Responses to lipids and expression of candidate G-protein
coupled receptors in K cells. a GIP responses to fatty acids. Mixed
intestinal cultures from the upper small intestine were incubated in
bath solution containing additions as indicated: control (Con),
oleoylethanolamide (OEA 10 μmol/l), linoleic acid (Linol,
100 μmol/l), fsk/IBMX (10 μmol/l of each). Number of wells: OEA,
9; Linol 11; fsk/IBMX, 9; fsk/IBMX + OEA, 6; fsk/IBMX + Linol, 9.
GIP was measured in the supernatant fraction and cell extracts, and is
expressed relative to basal secretion measured in parallel on the same
day (indicated by dashed line). Error bars represent 1 SE, and
significance is shown relative to baseline, analysed by single-factor
t test. **p<0.01, ***p<0.001. Significance of differences between
different combinations that included fsk/IBMX was tested by
regression analysis. †††p<0.001. Gene expression of Gpr40 (b),
Gpr119 (c) and Gpr120 (d) in Kpos (black columns) and Kneg cells
(white columns) from the upper small intestine relative to that of
β-actin as measured by quantitative RT-PCR. Each column represents
three or four samples. Data are presented as geometric mean, and the
error bar was calculated from the log(base 2) data. Significances of
comparisons between Kpos and Kneg cells were calculated by Student’s
t test performed on the log(base 2) data. **p<0.01, ***p<0.001
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using primary cultures of adult mouse small intestine. As
shown in Fig. 4a, GIP secretion was stimulated 1.34-fold
by 10 mmol/l glucose and 1.38-fold by 10 mmol/l glutamine,
an amino acid that potently stimulates GLP-1 release from
GLUTag cells [40]. Consistent with the finding that K cells
express KATP channels, we also observed a 1.25-fold
stimulation of secretion by 500 μmol/l tolbutamide. GIP
release was stimulated 1.21-fold by 10 mmol/l fructose and
2.6-fold by 100 mmol/l glucose. At such high concen-
trations, glucose may have non-specific effects, perhaps
related to its osmolarity. To test whether this effect of high
glucose might alternatively be attributable to the activation
of sweet taste receptors, we examined the response to the
artificial sweetener sucralose (1 mmol/l). However, consis-
tent with the undetectable levels of Tas1r2 and Gnat3 by
quantitative RT-PCR, sucralose did not stimulate GIP
release (Fig. 4b). GIP secretion was also increased 1.4-fold
by linoleic acid (100 μmol/l), 2.0-fold by the protein kinase C
activator phorbol 12-myristate 13-acetate (PMA; 1 μmol/l)
and 3.8-fold by a combination of fsk plus IBMX (fsk/
IBMX; 10 μmol/l of each), but was unaffected by OEA
(10 μmol/l), a low-affinity agonist of G-protein-coupled
receptor (GPR)119 (Figs 4b and 5a).
We next examined the effect of candidate secretagogues
in the presence of fsk/IBMX (Fig. 6). Under this condition,
glucose was a more potent stimulus, enhancing GIP
secretion 3.1-fold at 10 mmol/l, compared with the 1.34-
fold stimulation seen in the absence of fsk/IBMX. Secretion
was also stimulated 1.8-fold by glutamine (10 mmol/l), 1.4-
fold by linoleic acid (100 μmol/l), and again not by OEA or
sucralose under these conditions (Figs 5a and 6b).
Measurement of the dose–response relationship for glucose
in the presence of fsk/IBMX (Fig. 6a) revealed an ED50 of
0.6 mmol/l. Unlike the findings under basal conditions, in
fsk/IBMX we observed a highly significant, 1.7-fold stimu-
lation of GIP release by the non-metabolisable glucose
analogue α-methyl glucopyranoside (αMG; 10 mmol/l)
which was abolished by addition of phloridzin (5 μmol/l), a
specific inhibitor of SGLTs (Fig. 6b). Diazoxide (340 μmol/l)
inhibited αMG-triggered GIP secretion even below the
baseline level observed in fsk/IBMX alone. Taken together
with the finding that tolbutamide failed to trigger GIP
secretion under these conditions, this suggests that fsk/
IBMX acts at least in part via closure of KATP channels in
K cells. The greater effect of glucose in comparison with
αMG is not due to its combined action on both SGLT1- and
KATP channel-dependent pathways, as the further addition of
tolbutamide did not significantly enhance secretion com-
pared with that triggered by αMG alone (Fig. 6b). An
additional metabolic component of glucose is, however,
suggested by the finding that, under depolarising conditions
(fsk/IBMX, 30 mmol/l KCl and 340 μmol/l diazoxide),
10 mmol/l glucose triggered a further 1.3-fold increase in
GIP secretion (p=0.016, n=6).
In view of the stimulation of GIP secretion by linoleic
acid, PMA and elevated cAMP, we investigated whether
K cells express candidate G-protein-coupled receptors that
are coupled to the activation of these pathways. Recent reports
suggest that GPR40 and 120 (Gαq-coupled) as well as
GPR119 GascoupledÞð may play a role in the regulation
of enteroendocrine hormone release by long-chain fatty
acids and OEA, respectively [41–43], raising the possibility
Fig. 6 GIP secretion in the presence of elevated cAMP. a Mixed
intestinal cultures from the upper small intestine were incubated for 2–
4 h in bath solution containing fsk/IBMX (10 μmol/l of each) plus
different glucose concentrations, as indicated. GIP was measured in
the supernatant fraction and cell extracts, and is expressed relative
to the secretion in wells containing fsk/IBMX measured in parallel
on the same day. The data were fitted with a logistic equation
y ¼ Aþ 1 Að Þ= 1þ x=ED50ð Þnð Þ½ , with a maximal amplitude A=
2.1, an ED50=0.6 mmol/l and slope factor n of 1.3. Error bars
represent 1 SE, and significance is shown relative to fsk + IBMX,
analysed by single-factor t test; *p<0.05, **p<0.01. b GIP responses
to agonists in the presence of fsk/IBMX (10 μmol/l of each).
Experiments were carried out as in a, with additions as indicated:
control (Con), glucose (Gluc, 10 mmol/l), glutamine (Gln, 10 mmol/l),
tolbutamide (Tolb, 500 μmol/l), sucralose (Sucrl, 1 mmol/l), αMG
(10 mmol/l), phloridzin (Phlorid, 5 μmol/l), diazoxide (Diazox,
340 μmol/l). Number of wells: Gluc, 17; Gln, 6; Tolb, 20; Sucrl, 3;
αMG + Tolb, 13; αMG, 24; αMG + Phlorid, 6; αMG + Diazox, 6.
Secretion was normalised to that measured in fsk/IBMX alone,
measured in parallel on the same day (indicated by the dashed line).
Error bars represent 1 SE, and significance is shown relative to fsk/
IBMX, analysed by a single-factor t test; *p<0.05, **p<0.01, ***p<
0.001. Significance of differences between different combinations that
included αMG were tested by Student’s t test; †††p<0.001
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that these and/or related receptors might provide novel
targets for harnessing the endogenous release of incretin
hormones. By quantitative RT-PCR, we detected expression
of Gpr40 (also known as Ffar1), Gpr120 and Gpr119 in the
Kpos cell population, and only very low levels in the
corresponding Kneg cells (Fig. 5b–d and Table 1).
Discussion
To date, there has been relatively poor understanding of
how K cells release GIP, largely because living enter-
oendocrine cells are difficult to identify, and there are no
reliable models for studying GIP secretion in vitro. The
transgenic mice we have generated, with fluorescently
labelled K cells, enable the identification and purification
of K cells from freshly isolated tissue. Our data establish
that K cells express the potential glucose sensing machin-
ery, Kir6.2, Sur1, Gck and Sglt1, as well as lipid-sensing
receptors, Gpr40, Gpr119 and Gpr120. This correlates
functionally with our findings that GIP secretion was
stimulated by glucose, glutamine, fatty acids (linoleic acid),
PMA and cAMP elevation in primary intestinal cultures of
adult rodent intestine.
Immunofluorescence staining of fixed tissue and quan-
tification of Gip mRNA and protein in FACS-purified Kpos
cells confirmed that expression of the fluorescent protein in
GIP-Venus mice is specific to the K cell population. In
agreement with previous findings, we also detected gene
expression of Gcg and Pyy in the K cell pool, suggesting
some overlap with L cells. However, whereasGip expression
was six- to eightfold higher in K than L cells, proglucagon
expression showed the reverse pattern, with 90-fold higher
levels in L than in K cells. These findings are consistent
with the results of immunofluorescence studies which
showed that GIP and GLP-1 are colocalised in a subpop-
ulation of small intestinal K and L cells [29].
Glucose (10 mmol/l) triggered GIP secretion 1.3-fold
under basal conditions, but 3-fold in the presence of fsk/
IBMX, indicating a synergistic interaction between these
two stimulatory pathways. In fsk/IBMX, we could also
detect a 1.7-fold stimulation of GIP release by αMG,
indicating that secretion can be triggered by monosacchar-
ides independently of glycolytic metabolism. The respon-
siveness of GIP secretion to 10 mmol/l αMG, taken together
with the measured ED50 for glucose of 0.6 mmol/l, close to
the Km for glucose and αMG of SGLT1 (~0.3 mmol/l [44]),
suggests that SGLT1 plays a key role in glucose-triggered
GIP release. This is consistent with previous data from
whole intestinal preparations showing that GIP secretion
was triggered by luminal substrates of SGLTs [25]. The
submillimolar responsiveness of cultured K cells to glucose
and lack of responsiveness to sucralose, together with low
gene expression levels of sweet taste receptor subunits and
Gnat3 in Kpos cells by quantitative RT-PCR, suggest that
sweet taste receptors do not underlie the observed sugar-
triggered GIP release. Although these findings are consis-
tent with a recent report that orally administered sweeteners
do not trigger GIP or GLP-1 release in rats [45], other
recent studies have suggested that the sweet taste receptor
pathway underlies glucose-triggered incretin hormone secre-
tion [34, 35]. Further studies are required to evaluate whether
the low expression levels of TAS1 receptor subunits play a
role in GIP and GLP-1 secretion in vivo
The presence of functional KATP channels in K cells was
confirmed in secretion studies by the findings that GIP
release was triggered by tolbutamide under basal conditions
and inhibited by diazoxide in the presence of fsk/IBMX.
This was supported by the high expression levels of Kir6.2
and Sur1 mRNAs in purified K cells (>100-fold higher than
in neighbouring Kneg cells) and is consistent with a
previous observation that KIR6.2 was detectable in human
K cells by immunostaining [46]. As tolbutamide respon-
siveness was lost in the presence of fsk/IBMX, yet under
these conditions diazoxide inhibited secretion, our data
suggest that elevated cAMP brings about the closure of
KATP channels in K cells. cAMP-induced closure of KATP
channels in K cells could also allow small αMG-associated
transporter currents to become a sufficient trigger for GIP
release. As the open KATP current would only be expected
to inhibit the depolarising action of SGLT1 if these
conductances occurred in the same cell, the finding that
diazoxide inhibits the stimulatory action of αMG (in fsk/
IBMX) also supports the idea that SGLT1 in the K cells
themselves is involved in αMG-triggered GIP secretion.
The threefold greater secretory response to glucose than
to αMG could be explained by an additional metabolic
responsiveness to glucose, as glucose triggered a further
elevation of GIP secretion under conditions designed to
bypass any depolarising action of SGLT1. The ability of
fructose and glutamine to stimulate GIP release under basal
conditions also favours a role for metabolism in K cells. As
fructose is not a substrate for SGLT1, but may enter K cells
using the highly expressed facilitative glucose transporter
GLUT5 [47], the response to this sugar cannot be explained
by any known electrogenic uptake mechanism.
Elevation of cAMP by fsk/IBMX was a potent trigger of
GIP release in our experiments, and was synergistic with the
action of glucose. The effectiveness of cAMP elevation and
PMA as GIP secretagogues suggests that harnessing path-
ways coupled to the activation of adenylate cyclase and/or
protein kinase C might provide novel pathways to modulate
GIP release in vivo. It has been suggested, although not
definitively demonstrated, that lipids might physiologically
modulate the secretion of GLP-1 and GIP through activation
of the G-protein-coupled receptors GPR40, GPR119 and
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GPR120 [41, 42]. We detected a moderate but significant
increase in GIP secretion in response to the potential GPR40
and GPR120 agonist linoleic acid at both basal and elevated
cAMP concentrations, consistent with Gαq-coupled signal
transduction from these receptors. The GPR119 agonist
AR231453 was also recently shown to increase secretion of
GIP and GLP-1 in rodents in vivo, although the authors
were unable to demonstrate expression of Gpr119 in K cells
[42]. Our data show, however, that Gpr119 expression in
K cells is enhanced 330-fold compared with the neighbouring
cells, and is similar to that found in small intestinal and
colonic L cells (data not shown). These new tools to measure
the expression profile of adult K cells and the functional
responsiveness of GIP secretion in primary culture offer
unique future opportunities to interrogate the mechanisms
underlying GIP release.
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